LNTH - FDA Ok's Lantheus new formulation of ultrasound imaging agent

Lantheus (LNTH) climbs 12% in post market after the FDA approves the supplemental marketing application for Definity Room Temperature (Definity RT), a modified formulation of Definity that allows both storage and shipment at room temperature (previously approved formulation requires refrigerated storage).Definity (Perflutren Lipid Microsphere) is an injectable suspension, an intravenous ultrasound enhancing agent.The activation of Definity RT will be achieved using the VIALMIX RFID device, which was approved in August this year.The composition of matter U.S. issued patent for Definity RT has an expiration date of 2035.

For further details see:

FDA Ok's Lantheus new formulation of ultrasound imaging agent